Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
|Videos|March 16, 2016
Comorbid Conditions that May Influence Asthma and COPD Treatment Selection and Dosing
Michael Cawley, BS, PharmD, RRT, CPFT, FCCM, professor of clinical pharmacy at the University of the Sciences, discusses what comorbid conditions to look out for among asthma and COPD patients.
Advertisement
Michael Cawley, BS, PharmD, RRT, CPFT, FCCM, professor of clinical pharmacy at the University of the Sciences, discusses what comorbid conditions to look out for among asthma and COPD patients.
This video was recorded at APhA's 2016 Annual Meeting and Exposition in Baltimore, Maryland.
Advertisement
Related to this article
Findings presented at the European Respiratory Society Congress 2026 suggest semaglutide may offer respiratory benefits beyond its approved diabetes and obesity indications.
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Influenza Vaccines Continue to Reduce Severe Disease and Death Across High-Risk Groups, Evidence Review Finds
4
Building a BCMA Bispecific Around the Patient Experience, Not Just the Molecule
5